A phase 2, international, multicenter, randomized, open-label, parallel group to evaluate the efficacy and safety of CC-486 (Oral Azacitidine) alone in combination with Durvalumab (MEDI4736) in subjects with myelodysplastic syndromes who fail to achieve an objective response to treatment with azacitidine for injection or decitabine